1. Home
  2. PHGE vs VVOS Comparison

PHGE vs VVOS Comparison

Compare PHGE & VVOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHGE
  • VVOS
  • Stock Information
  • Founded
  • PHGE 2015
  • VVOS 2016
  • Country
  • PHGE Israel
  • VVOS United States
  • Employees
  • PHGE N/A
  • VVOS N/A
  • Industry
  • PHGE Biotechnology: Pharmaceutical Preparations
  • VVOS Medical Specialities
  • Sector
  • PHGE Health Care
  • VVOS Health Care
  • Exchange
  • PHGE Nasdaq
  • VVOS Nasdaq
  • Market Cap
  • PHGE 14.6M
  • VVOS 14.8M
  • IPO Year
  • PHGE N/A
  • VVOS 2020
  • Fundamental
  • Price
  • PHGE $0.50
  • VVOS $2.39
  • Analyst Decision
  • PHGE Strong Buy
  • VVOS Strong Buy
  • Analyst Count
  • PHGE 2
  • VVOS 2
  • Target Price
  • PHGE $20.00
  • VVOS $6.10
  • AVG Volume (30 Days)
  • PHGE 85.8K
  • VVOS 125.1K
  • Earning Date
  • PHGE 05-15-2025
  • VVOS 05-15-2025
  • Dividend Yield
  • PHGE N/A
  • VVOS N/A
  • EPS Growth
  • PHGE N/A
  • VVOS N/A
  • EPS
  • PHGE N/A
  • VVOS N/A
  • Revenue
  • PHGE N/A
  • VVOS $14,628,000.00
  • Revenue This Year
  • PHGE N/A
  • VVOS $17.40
  • Revenue Next Year
  • PHGE N/A
  • VVOS $20.89
  • P/E Ratio
  • PHGE N/A
  • VVOS N/A
  • Revenue Growth
  • PHGE N/A
  • VVOS 9.47
  • 52 Week Low
  • PHGE $0.45
  • VVOS $1.97
  • 52 Week High
  • PHGE $4.90
  • VVOS $6.28
  • Technical
  • Relative Strength Index (RSI)
  • PHGE 40.96
  • VVOS 45.36
  • Support Level
  • PHGE $0.45
  • VVOS $2.24
  • Resistance Level
  • PHGE $0.52
  • VVOS $2.49
  • Average True Range (ATR)
  • PHGE 0.04
  • VVOS 0.26
  • MACD
  • PHGE -0.00
  • VVOS -0.01
  • Stochastic Oscillator
  • PHGE 39.31
  • VVOS 31.13

About PHGE BiomX Inc. COmmon Stock

BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).

About VVOS Vivos Therapeutics Inc.

Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.

Share on Social Networks: